Aardvark Therapeutics Inc. (NASDAQ:AARD) shares are down during Monday’s premarket session following the company’s announcement to voluntarily pause its Phase 3 HERO trial for Prader-Willi Syndrome.The decision comes as the company is conducting a comprehensive review of safety data.Observed Side EffectsThe company on Friday revealed that it will not announce topline data from the HERO trial as previously anticipated in the third quarter of 2026. This pause was prompted by reversible cardiac observations at higher than target therapeutic doses found during routine safety monitoring in a healthy volunteer study.Aardvark’s CEO, Tien Lee, emphasized the commitment to patient safety and the importance of evaluating the signals seen at elevated doses of ARD-101. The company plans to continue collaborating closely with the FDA and the Prader-Willi ...Full story available on Benzinga.com
Why Is Aardvark Therapeutics Stock Sinking Monday?
